17554 Holly Well Ave., Tampa, FL 33598
June 30, 2026 Management reported Medifast Q2 results, as follows: Second Quarter 2026 • Revenue: $76.4 million, with revenue per active earning coach of $6,529 • Independent active earning coaches of 11,700 • Net loss of $3.1 million or $0.28 loss per diluted share (“EPS”) • Cash, Cash Equivalents, and Investment Securities of $169.8 million […]
Medifast Reports Q2 2026 Results Read More »
July 17, 2026 Medifast introduces a new program called Trilivy(TM), a science-backed metabolic health system. Trilivy replaces the former Optavia plan, that was focused only on weight loss. According to the press release: The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary
Medifast Launches Trilivy, Replaces Optavia Read More »
August 5, 2026 WW reported its Q2 results today. Management said: “We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “Core+, our high-value
Weight Watchers Reports Q2 Results Read More »
May 7, 2026 According to management: “We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging
Weight Watchers Reports Q1 2026 Results Read More »
May 6, 2026 Medifast reports its first quarter 2026 results. According to management: “We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been
Medifast Reports Q1 2026 Results Read More »
March 17, 2026 Weight Watchers reports its 2025 results yesterday. The firm’s revenues came in at $710 million, a 9.6% decline from 2024 revenues of $786 million. The company is expecting an 11% decrease in 2026 revenues, to between $620 and $635 million. 2025 Total Revenue and Adjusted EBITDA above high end of previously provided
Weight Watchers Reports Q4 & Full Year 2025 Results, 2026 Guidance Read More »
Feb. 18, 2026 Medifast reported full-year and Q4 2025 results on February 17, 2026. 2025 revenues came in at $386 million – a 36% decrease from $602 million in 2024. The company employed 16,100 active earning Optavia health coaches, who had quarterly earnings of $4,664 (or $18,656 on an annual rate). “As we enter 2026,
Medifast Reports Q4 and Full Year 2025 Results Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy
Novo Nordisk Lowers Weight Loss Drug Prices Read More »
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for
Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »